- Главная
- Разное
- Дизайн
- Бизнес и предпринимательство
- Аналитика
- Образование
- Развлечения
- Красота и здоровье
- Финансы
- Государство
- Путешествия
- Спорт
- Недвижимость
- Армия
- Графика
- Культурология
- Еда и кулинария
- Лингвистика
- Английский язык
- Астрономия
- Алгебра
- Биология
- География
- Детские презентации
- Информатика
- История
- Литература
- Маркетинг
- Математика
- Медицина
- Менеджмент
- Музыка
- МХК
- Немецкий язык
- ОБЖ
- Обществознание
- Окружающий мир
- Педагогика
- Русский язык
- Технология
- Физика
- Философия
- Химия
- Шаблоны, картинки для презентаций
- Экология
- Экономика
- Юриспруденция
Why Shares of Inotek Pharmaceuticals Sank 23% in September презентация
Содержание
What happened? Biotech stocks were sold off in September, as the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) fell 9% during the month.
Слайд 2What happened?
Biotech stocks were sold off in September, as the iShares
Nasdaq Biotechnology ETF (NASDAQ: IBB) fell 9% during the month.
Слайд 3What happened?
Shares of Inotek Pharmaceuticals (NASDAQ: ITEK), fell much harder, down
23% in the month.
Слайд 4So What?
Inotek did not release any news during September, so the
sell-off likely had nothing to do with the company itself.
Inotek’s lead drug Trabodenoson, a potential glaucoma treatment, is entering phase 3 clinical trials this quarter. Top-line data is expected in 2016.
Inotek’s lead drug Trabodenoson, a potential glaucoma treatment, is entering phase 3 clinical trials this quarter. Top-line data is expected in 2016.
Слайд 5Now what?
Trabodenoson holds huge potential, with peak sales estimates around $900
million.
Inotek completed a $79 million public secondary offering in August, so it appears to be well capitalized.
If you liked Inotek before the sell-off, I see no reason to change your opinion now.
Inotek completed a $79 million public secondary offering in August, so it appears to be well capitalized.
If you liked Inotek before the sell-off, I see no reason to change your opinion now.
